Conference on Bacteriophages: Biology, Dynamics, and Therapeutics (On-Demand)

The inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, was held on October 12 to 14, 2025, in Washington, DC, USA. Academic and other investigators met for this 2.5-day conference that included state-of-the-art invited talks, symposia, and workshops, as well as abstract-driven presentations focused on recent scientific advances and future clinical applications of bacteriophages.

Registered Conference Attendees

REMINDER: Registered attendees can continue to access all conference materials through the App, including on-demand sessions, the eAbstract book, ePosters, and claiming CME credit.

If you attended in person, use your IAS–USA login information to access all conference content.

Purchase On-Demand Access

Registration remains open to provide access to the full conference materials—on-demand session recordings, ePosters, and all related resources. We encourage you to register promptly and take advantage of this valuable content.

For On-Demand Registrants only. Use your IAS–USA login information to access all conference content.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA identified and resolved ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Continuing Education Credits

IAS-USA Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.